1.	Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 100138, 10-C-0138, NCT01143545
2.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
3.	Preoperative Treatment of Patients With High Risk Thymoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: VHS07.0006a, NCT00387868
4.	Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDKO-125a-006, 2009-014338-79, NCT01011439
5.	Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-038, NCT01025089
6.	Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Phase: Phase II Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: SLR IRB#09-207, NCT01163552
7.	Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDKO-125a-007, NCT01301391
8.	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110096, 11-C-0096, NCT01306045
9.	Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-01-040, NCT01312324
10.	Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: SIM-90, NCT01327235
11.	A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: THOR0003, SU-01142011-7369, NCT01364727
12.	A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: I206, NCT01396408
13.	3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230DIC03, 2011-002872-17, NCT01563354
14.	Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120118, 12-C-0118, NCT01621568
15.	Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120151, 12-C-0151, NCT01624090
16.	Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 61 and over Sponsor: Other Protocol IDs: DSHNHL-2010-1, 2010-024004-98, NCT01686321
17.	Sunitinib and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-03112, 050909, U01CA132194, CINJ-050801, 050801, 0220080281, NCT00813423
18.	Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Pro00017361, NCT00921739
19.	Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Mediastinal or Chest Wall Neoplasms, or Lung Metastases from Cancers of Non-Thoracic Origin Phase: No phase specified Type: Biomarker/Laboratory analysis, Diagnostic, Tissue collection/Repository Status: Active Age: Any age Sponsor: NCI Protocol IDs: NCI-06-C-0014, NCI-P6650, NCT00447447
20.	Controlled Trial Comparing the Performance of 22 Gauge Versus 25 Gauge EUS-FNA Needles (FNA-22G-25G) Phase: No phase specified Type: Diagnostic, Health services research Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: EUS-FNA-DK-PV-2009, NCT01016288
21.	Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943) Phase: No phase specified Type: Diagnostic Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: HP-00043875, NCT01016938
22.	Nonmyeloablative Allogeneic Transplant Phase: No phase specified Type: Treatment Status: Active Age: 18 to 72 Sponsor: Other Protocol IDs: SCC-01-499, NCT01272817
23.	Molecular Analysis of Thoracic Malignancies Phase: No phase specified Type: Biomarker/Laboratory analysis, Natural history/Epidemiology Status: Active Age: 18 and over Sponsor: Other Protocol IDs: THOR0004, SU-06232011-7986, 21319, NCT01385722
24.	Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 11-1621, NCT01580982
25.	Electronic Patient Reported Symptom Assessment Phase: No phase specified Type: Health services research, Supportive care Status: Active Age: 18 and over Sponsor: Other Protocol IDs: STU00064629, NCT01833637